Microbot Medical (NASDAQ: MBOT) more than doubles Q2 revenue as LIBERTY adoption rises
Rhea-AI Filing Summary
Microbot Medical Inc. reports strong commercial momentum for its LIBERTY Endovascular Robotic System in the second quarter of 2026. The company achieved greater than 100% growth in both revenue and new customers for the quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as procedure volume also increased.
This performance follows the Full Market Release of the LIBERTY System on April 13, 2026, with new adoptions by leading health systems in several U.S. states. Microbot also expanded distribution through an agreement with Lovell Government Services to access federal healthcare systems. The company grew its U.S. sales footprint from 4 to 8 territories during the quarter and aims for 12 by year-end, received marketing clearance in Israel as its first market outside the U.S., and agreed to establish a second manufacturing site to support rising demand.
Positive
- Greater than 100% quarter-over-quarter growth in both revenue and new customers for Q2 2026 compared to Q1 2026, alongside higher procedure volumes at existing LIBERTY sites, signals strong early commercial traction.
- Accelerating commercial expansion with U.S. sales territories increasing from 4 to 8 in Q2 2026 and a goal of 12 by year-end, plus new access to federal healthcare systems via Lovell Government Services.
- International and capacity build-out through Israeli marketing clearance for LIBERTY as the first market outside the U.S. and an agreement for a second manufacturing site to support future demand and potential margin benefits.
Negative
- None.
Insights
Microbot shows rapid early commercial traction for LIBERTY with global expansion steps.
Microbot Medical reports greater than 100% quarter-over-quarter growth in revenue and new customers for Q2 2026, driven by the Full Market Release of its LIBERTY Endovascular Robotic System in mid-April. Higher procedure volumes at existing sites reinforce that early adopters are increasing usage, not just purchasing systems.
Commercial reach expanded as U.S. sales territories grew from 4 to 8, with a stated goal of 12 by the end of 2026. An agreement with Lovell Government Services opens a path to federal healthcare systems, and marketing clearance in Israel marks the first international approval. A second manufacturing site is intended to support demand and may aid long-term margin expansion as volumes scale.
These disclosures indicate meaningful early uptake of LIBERTY and deliberate capacity and geographic expansion. Future company filings may quantify absolute revenue levels, federal channel progress, international adoption and the financial impact of added manufacturing capacity.
8-K Event Classification
Key Figures
Key Terms
Full Market Release financial
Limited Market Release (LMR) financial
LIBERTY® Endovascular Robotic System technical
marketing clearance regulatory
Veterans Health Administration (VHA) other
Military Health System (MHS) other
FAQ
What growth did Microbot Medical (MBOT) report for Q2 2026?
What is driving Microbot Medical’s revenue and customer growth in 2026?
How is Microbot Medical expanding its sales footprint for the LIBERTY system?
What new channels and markets is Microbot Medical (MBOT) entering?
How is Microbot Medical preparing its manufacturing capacity for LIBERTY?
What is the LIBERTY Endovascular Robotic System developed by Microbot Medical?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
The information contained below in Item 8.01 is hereby incorporated by reference into this Item 7.01.
A press release relating to such information, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.
Item 8.01 Other Events.
Microbot Medical Inc. has reported a greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026.
Forward Looking Statements
This Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number |
Description | |
| 99.1 | Press Release | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| MICROBOT MEDICAL INC. | ||
| By: | /s/ Harel Gadot | |
| Name: | Harel Gadot | |
| Title: | Chief Executive Officer, President and Chairman | |
Date: July 7, 2026
Exhibit 99.1
Microbot Medical® Reports Over 100% Revenue and Customer Growth
as Procedure Volume also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April
Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026
HINGHAM, Mass., July 7, 2026 – Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026. The performance reflects the successful commencement of the Full Market Release of the LIBERTY System on April 13, 2026, as health systems in several key markets adopted the system during the second quarter, including leading health systems in Massachusetts, North Carolina, Michigan and Pennsylvania. In addition, the Company entered into an agreement with Lovell Government Services Inc. to serve federal healthcare systems, such as the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of War, and the Indian Health Service (IHS).
Furthermore, health systems that had adopted the LIBERTY system during the Limited Market Release (LMR), have increased their procedure volume in the second quarter ended June 30, 2026 due to site expansion and more users migrating to the system, compared to the first quarter ended March 31, 2026. With the rising interest from leading health systems, the Company broadened its sales footprint from 4 to 8 sales territories during the second quarter of 2026, and is on track to have12 territories across the U.S. by the end of the year.
Moreover, the Company recently received marketing clearance for the LIBERTY system from the Israeli Ministry of Health’s AMAR Division, making Israel the first country outside of the U.S. to approve the system. To ensure the Company has the capacity to meet current and future demand, it recently entered into an agreement to establish a second manufacturing site, positioning the Company for potential long-term margin expansion as volumes scale.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com